Take This Into Account Before Investing in TECH

Large-cap Health Care company Bio-Techne has moved -0.3% so far today on a volume of 122,084, compared to its average of 874,041. In contrast, the S&P 500 index moved 0.0%.

Bio-Techne trades -28.92% away from its average analyst target price of $100.7 per share. The 13 analysts following the stock have set target prices ranging from $86.0 to $120.0, and on average have given Bio-Techne a rating of buy.

Anyone interested in buying TECH should be aware of the facts below:

  • Bio-Techne's current price is 263.7% above its Graham number of $19.68, which implies that at its current valuation it does not offer a margin of safety

  • Bio-Techne has moved -17.0% over the last year, and the S&P 500 logged a change of 10.0%

  • Based on its trailing earnings per share of 1.76, Bio-Techne has a trailing 12 month Price to Earnings (P/E) ratio of 40.7 while the S&P 500 average is 15.97

  • TECH has a forward P/E ratio of 30.7 based on its forward 12 month price to earnings (EPS) of $2.33 per share

  • The company has a price to earnings growth (PEG) ratio of 3.24 — a number near or below 1 signifying that Bio-Techne is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 5.74 compared to its sector average of 4.16

  • Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

  • Based in Minneapolis, the company has 3,050 full time employees and a market cap of $11.32 Billion. Bio-Techne currently returns an annual dividend yield of 0.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.